Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study
Romanian Journal of Internal Medicine · 01.06.2018 · 56 (2) · 96-101
DOI: 10.2478/rjim-2018-0002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Romanian Journal of Internal Medicine, online erschienen am 17.05.2018. Verfasst von Maria Alexandra Barbu und 3 weiteren Autor:innen. Beteiligte Einrichtung: "UMF Carol Davila" School of Medicine, Bucharest. Hauptthemen laut MEDLINE: Quality of Life. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous reactions, that is why adequate understanding and management of these side effects is very important for drug adherence and patients’ quality of life. Materials and methods . We conducted a prospective study of consecutive patients who received oncologic treatment in our institution and presented with dermatologic side effects. The severity of skin toxicity was assessed using the DLQI score and patients were prospectively followed to evaluate response to therapy. Univariate analysis of factors influencing the impact of skin toxicity on patient QOL was conducted.
Results
52 patients were enrolled in the study. Patients who developed grade 3 and 4 skin toxicity had a higher DLQI score, with a greater impact on quality of life, but with better clinical outcome at 3 months follow-up, based on RECIST. Patients with moderate or severe cutaneous AE were more likely to achieve complete or partial response to therapy than those with mild AE (16/33 vs. 3/19, p = 0.035). Interestingly, female patients had a significantly poorer quality of life than male patients as assessed by the DLQI score (7.28 ± 7 vs . 3.7 ± 3.6, p = 0.038).
Conclusion
Cutaneous side effects are often encountered in cancer patients and their severity can be a surrogate marker for a positive clinical tumor response to therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- "UMF Carol Davila" School of Medicine, Bucharest.
- Medical Oncology Department, Elias University Emergency Hospital, Bucharest.
- Dermatooncology Department, Elias University Emergency Hospital, Bucharest.
Zitieren
APA
Barbu, M. A., Niţipir, C., Voiosu, T., & Giurcăneanu, C. (2018). Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study. Romanian Journal of Internal Medicine, 56(2), 96-101. https://doi.org/10.2478/rjim-2018-0002
Vancouver
Barbu MA, Niţipir C, Voiosu T, Giurcăneanu C. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study. Romanian Journal of Internal Medicine. 2018;56(2):96-101. doi:10.2478/rjim-2018-0002
BibTeX
@article{Barbu2018,
author = {Barbu, Maria Alexandra and Niţipir, Cornelia and Voiosu, Theodor and Giurcăneanu, Călin},
title = {Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study},
journal = {Romanian Journal of Internal Medicine},
year = {2018},
volume = {56},
number = {2},
pages = {96--101},
doi = {10.2478/rjim-2018-0002}
}
EUVIMED